Edition:
United States

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

18.82USD
10:49am EST
Change (% chg)

$0.06 (+0.32%)
Prev Close
$18.76
Open
$18.75
Day's High
$19.01
Day's Low
$18.44
Volume
41,629
Avg. Vol
218,618
52-wk High
$24.30
52-wk Low
$11.48

Summary

Name Age Since Current Position

Derek Chalmers

54 President, Chief Executive Officer, Director

Mani Mohindru

46 2017 Chief Financial Officer, Chief Strategy Officer

Scott Terrillion

55 2016 Chief Compliance Officer, General Counsel, Secretary

Frederique Menzaghi

51 Vice President, Research & Development

Joana Goncalves

2018 Chief Medical Officer

Martin Vogelbaum

54 2010 Lead Independent Director

Christopher Posner

49 2018 Director

Harrison Bains

74 2014 Independent Director

Jeffrey Ives

67 2014 Independent Director

Biographies

Name Description

Derek Chalmers

Dr. Derek Chalmers, Ph.D. serves as a President, Chief Executive Officer and a Director at Cara Therapeutics, Inc. Dr. Chalmers has over 24 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow. Dr. Chalmers’ qualifications to sit on our Board of Directors include his leadership, executive, managerial and business experience, historical knowledge of our company and his background and experience in the biotechnology industry, including having been a founder of a prior biotechnology company.

Mani Mohindru

Dr. Mani Mohindru, Ph.D., serves as Chief Financial Officer, Chief Strategy Officer of the Company. effective from August 15, 2017. Dr. Mohindru brings more than a decade of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq:CRIS), where she was instrumental in the development and management of overall corporate strategy. She was also responsible for the company's engagement with the investment community, building extensive relationships with industry analysts and investors. Earlier in her career, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University.

Scott Terrillion

Mr. Scott M. Terrillion serves as General Counsel, Secretary and Chief Compliance Officer of the company. Mr. Terrillion brings over 20 years of diverse pharmaceutical industry experience from varying legal and business roles in the public, private and not-for-profit sectors. Mr. Terrillion spent 15 years at Boehringer Ingelheim Pharmaceuticals, Inc., where he served as Vice President, Associate General Counsel. At Boehringer, Mr. Terrillion built and led the legal team supporting the global company’s US human pharmaceutical business during a period of rapid, industry-leading growth. Mr. Terrillion also spent two years at Mesoblast, Inc., a publicly traded emerging biotech, as the company’s Vice President, Associate General Counsel and Head of Compliance. Mr. Terrillion began his legal career at Nixon, Hargrave, Devans & Doyle (now Nixon Peabody), a large general practice law firm, where he was an associate in the Health Care and Technology/Intellectual Property Practice groups. A licensed pharmacist, Mr. Terrillion began his professional career as a community pharmacist and later served as Director of Pharmacy for Preferred Care, Inc., a HMO insurance provider. Mr. Terrillion received his BS in Pharmacy from the Albany College of Pharmacy and Health Sciences, where he serves on the Board of Trustees, and a Juris Doctor, magna cum laude, from Albany Law School. He is a member of the New York bar.

Frederique Menzaghi

Dr. Frederique Menzaghi, Ph.D., serves as a Vice President Research and Development of Cara Therapeutics, Inc. She has seventeen years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. She previously served as Vice President Pharmacology and Business Development at Psychogenics Inc., and was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals. Prior to that, she established and directed a preclinical research laboratory at SIBIA Neurosciences. She has experience with corporate partnering with pharmaceutical companies including Eli Lilly and J&J. She received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a Master of Science in Clinic al Psychology from the University of Nancy.

Joana Goncalves

Dr. Joana Goncalves is Chief Medical Officer of the Company. Dr. Goncalves brings more than 17 years of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Vice President, Medical Affairs for Dermatology and Neurology at Celgene Corporation where she was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA® for psoriatic arthritis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma A/S. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa.

Martin Vogelbaum

Mr. Martin Vogelbaum serves as an Lead Independent Director of the company. Mr. Vogelbaum has served as a partner of Rho Ventures since 2005 and primarily focuses on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 19 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Mr. Vogelbaum currently serves as a director of Inotek Pharmaceuticals Corporation. In 2014, Mr. Vogelbaum served as a member of the board of directors of Nephrogenex, Inc. and from 2007 to 2010, Mr. Vogelbaum served as a member of the board of directors of Middlebrook Pharmaceuticals, Inc. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD). Mr. Vogelbaum received his A.B. in biology and history from Columbia University.

Christopher Posner

Mr. Christopher Posner is Director of the company. He has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. Since July 2017, he has been the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University.

Harrison Bains

Mr. Harrison M. Bains, Jr., serves as an Independent Director of the Company. From 1988 through his retirement in 2004, Mr. Bains served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as a director of BG Medicine, Inc., as a director and former chairman of the Mercer Funds, Inc., a registered investment company, and as a director of Bank of America Funds. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007, and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013. Mr. Bains earned an M.B.A from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School.

Jeffrey Ives

Dr. Jeffrey L. Ives, Ph.D., serves as an Independent Director of the Company. From 2008 until 2013, Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001-2007, served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University.

Basic Compensation

Name Fiscal Year Total

Derek Chalmers

3,521,650

Mani Mohindru

4,046,470

Scott Terrillion

--

Frederique Menzaghi

780,510

Joana Goncalves

--

Martin Vogelbaum

292,943

Christopher Posner

--

Harrison Bains

260,443

Jeffrey Ives

257,943
As Of  30 Dec 2017